Rheumatoid Arthritis Clinical Trial
— MUSICAOfficial title:
A Multicenter, Double-Blind, Randomized, Parallel-Arm Study to Determine the Effect of Methotrexate Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis Treated With Adalimumab (MUSICA)
Verified date | January 2014 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis (RA).
Status | Completed |
Enrollment | 309 |
Est. completion date | January 2013 |
Est. primary completion date | January 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult subjects with moderately to severely active rheumatoid arthritis - Subjects must have a DAS28(CRP) (Disease Activity Score using C-Reactive Protein) greater than or equal to 3.2 at baseline (there is no minimum CRP score required to qualify) - Subjects must have at least 5/68 tender joints plus 5/66 swollen joints assessed at screening or baseline - Subject must treated with and MTX (methotrexate) dose (oral and/or injectable) of 15 mg or more per week (no upper limit on dose) for at least 12 weeks prior to screening - Subject is either biologic-naïve or has only one prior biologic disease-modifying antirheumatic drug (i.e. abatacept, anakinra, certolizumab, etanercept, golimumab, infliximab, or tocilizumab) Exclusion Criteria: - Previous exposure to adalimumab (Humira), rituximab (Rituxan), natalizumab (Tysabri), efalizumab (Raptiva) - Subject has been treated with intra-articular or parenteral administration of corticosteroids within 4 weeks of screening - Subject has diagnosis or history of gout or pseudogout - Subject has undergone joint surgery within 12 weeks of screening (at joints to be assessed by ultrasound) - Subject has history of chronic arthritis diagnosed before age 16 years |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Puerto Rico | Site Reference ID/Investigator# 38691 | San Juan | |
Puerto Rico | Site Reference ID/Investigator# 60850 | San Juan | |
Puerto Rico | Site Reference ID/Investigator# 60851 | Vega Baja | |
United States | Site Reference ID/Investigator# 38263 | Asheville | North Carolina |
United States | Site Reference ID/Investigator# 38202 | Bend | Oregon |
United States | Site Reference ID/Investigator# 38981 | Bowling Green | Kentucky |
United States | Site Reference ID/Investigator# 38983 | Bronx | New York |
United States | Site Reference ID/Investigator# 40124 | Clifton | New Jersey |
United States | Site Reference ID/Investigator# 38086 | Covington | Louisiana |
United States | Site Reference ID/Investigator# 37980 | Dallas | Texas |
United States | Site Reference ID/Investigator# 44888 | Dallas | Texas |
United States | Site Reference ID/Investigator# 43049 | Danbury | Connecticut |
United States | Site Reference ID/Investigator# 38265 | Duncansville | Pennsylvania |
United States | Site Reference ID/Investigator# 39023 | Eugene | Oregon |
United States | Site Reference ID/Investigator# 40125 | Fall River | Massachusetts |
United States | Site Reference ID/Investigator# 38087 | Franklin | Wisconsin |
United States | Site Reference ID/Investigator# 38978 | Freehold | New Jersey |
United States | Site Reference ID/Investigator# 38261 | Greenville | North Carolina |
United States | Site Reference ID/Investigator# 37981 | Hemet | California |
United States | Site Reference ID/Investigator# 43050 | Houston | Texas |
United States | Site Reference ID/Investigator# 38982 | Huntsville | Alabama |
United States | Site Reference ID/Investigator# 38082 | Jackson | Tennessee |
United States | Site Reference ID/Investigator# 38687 | Jacksonville | Florida |
United States | Site Reference ID/Investigator# 65490 | Las Vegas | Nevada |
United States | Site Reference ID/Investigator# 38688 | Lawrenceville | Georgia |
United States | Site Reference ID/Investigator# 44823 | Little Rock | Arkansas |
United States | Site Reference ID/Investigator# 40208 | Long Beach | California |
United States | Site Reference ID/Investigator# 39024 | Mayfield Village | Ohio |
United States | Site Reference ID/Investigator# 38689 | Meridian | Idaho |
United States | Site Reference ID/Investigator# 42044 | Mesa | Arizona |
United States | Site Reference ID/Investigator# 40105 | Miami | Florida |
United States | Site Reference ID/Investigator# 40127 | Oklahoma City | Oklahoma |
United States | Site Reference ID/Investigator# 37983 | Phoenix | Arizona |
United States | Site Reference ID/Investigator# 44344 | Richmond | Virginia |
United States | Site Reference ID/Investigator# 38085 | Rock Island | Illinois |
United States | Site Reference ID/Investigator# 38423 | Sacramento | California |
United States | Site Reference ID/Investigator# 43735 | San Antonio | Texas |
United States | Site Reference ID/Investigator# 38083 | Sarasota | Florida |
United States | Site Reference ID/Investigator# 38084 | Seattle | Washington |
United States | Site Reference ID/Investigator# 38542 | Seattle | Washington |
United States | Site Reference ID/Investigator# 40210 | Seattle | Washington |
United States | Site Reference ID/Investigator# 38264 | Smithtown | New York |
United States | Site Reference ID/Investigator# 38424 | Spokane | Washington |
United States | Site Reference ID/Investigator# 40128 | Springfield | Illinois |
United States | Site Reference ID/Investigator# 38203 | Tacoma | Washington |
United States | Site Reference ID/Investigator# 38686 | Tuscaloosa | Alabama |
United States | Site Reference ID/Investigator# 38204 | Victorville | California |
United States | Site Reference ID/Investigator# 40123 | Voorhees | New Jersey |
United States | Site Reference ID/Investigator# 40762 | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) |
United States, Puerto Rico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Serum Adalimumab Trough Concentrations at Week 24 | Serum trough concentrations of adalimumab assessed at week 24 (24 weeks after the 1st dose). | Week 24 | No |
Primary | Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24 | The DAS28(CRP) score includes 28 tender joint counts, 28 swollen joint counts, C-reactive protein, and participant's global assessment of disease activity. Scores on the DAS28(CRP) range from 0 to 10. A DAS28(CRP) score = 5.1 indicates high disease activity, and a DAS28(CRP) score < 2.6 indicates clinical remission. Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline DAS28(CRP) value, treatment group, and prior methotrexate dose group. | Week 24 | No |
Secondary | Percentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 24 | PD U/S assessed the severity of synovial inflammation in both hands (bilateral wrists, metacarpophalangeal joints 2, 3, 5, and metatarsophalangeal joint 5). Bilateral images based on dorsal midline imaging of the wrist, dorsal and volar imaging of metacarpophalangeal joints, and dorsal imaging alone of metatarsophalangeal joints are scored using a 4-grade scale: grade 0 or normal = normal joint (no Doppler signal); grade 1 or mild = mild synovitis (= 3 isolated signals); grade 2 or moderate = moderate synovitis (> 3 isolated signals or a confluent signal in < 50% of synovial area); grade 3 or marked = marked synovitis (signals in = 50% of the synovial area). Each image is rated 0 to 3, for a total possible score ranging from 0 to 48 (16*0, 16*3) for 2 hands. Higher grade/score=more severe disease. Change = week 24 score - baseline score. | Baseline, 24 weeks | No |
Secondary | Percentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 24 | Response, as defined by ACR50 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: = 50% improvement in tender joint count; = 50% improvement in swollen joint count; and = 50% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein). | Baseline, 24 weeks | No |
Secondary | Percentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 24 | Response, as defined by ACR70 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: = 70% improvement in tender joint count; = 70% improvement in swollen joint count; and = 70% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein). | Baseline, 24 weeks | No |
Secondary | Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) = -0.22 at Week 24 | The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high dependency disability). The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from baseline of = -0.22. Normal physical function is defined by HAQ-DI score of < 0.5. Negative change from baseline in the overall score indicates improvement. | Baseline, 24 weeks | No |
Secondary | Percent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24 | The least squares mean percentage change in MOS Sleep Problem Index 9 from baseline to week 24. The MOS Sleep Problem Index 9 consists of 9 questions to assess sleep, including how long it takes the participant to fall asleep (1=0 to 15 minutes, to 5=more than 60 minutes); and aspects of related to quality of sleep, including how often the participant felt that the sleep was not quiet, felt rested upon waking, awakened short of breath or with a headache, felt drowsy during the day, had trouble falling sleep, how often were awaken, had trouble staying awake during the day, and got needed amount of sleep (1=all the time; 5=none of the time). Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline MOS Sleep Problem Index value, treatment group, and prior methotrexate dose group. | Baseline, 24 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |